Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the Parkinson's caregiver research overview.
Short answer. Deep brain stimulation (DBS) is one of the most studied surgical therapies in neurology, with consistent evidence that for appropriately selected candidates it dramatically reduces motor fluctuations and dyskinesia and improves quality of life (Deuschl et al., 2006; Krack et al., 2019). It is not a cure and does not stop disease progression. Candidacy is narrow and specific: good levodopa response, problematic motor fluctuations or dyskinesia, no significant cognitive impairment, no untreated psychiatric illness, and a realistic understanding of what the surgery will and will not deliver (Lang et al., 2006; Bronstein et al., 2011).
What DBS actually is
DBS involves the surgical implantation of thin electrodes into specific brain targets, connected by a wire under the skin to a battery-powered pulse generator (the "neurostimulator") implanted in the upper chest. The pulse generator delivers continuous high-frequency electrical stimulation that modulates abnormal circuit activity in the basal ganglia.
The targets used in PD are:
- Subthalamic nucleus (STN-DBS) — the most common target. Strong reduction in motor symptoms, often allowing a 30-50% reduction in levodopa dose. Some risk of mood and cognitive side effects.
- Globus pallidus internus (GPi-DBS) — comparable motor benefit. Less levodopa reduction. Generally fewer mood and cognitive side effects. Often preferred for older candidates or those with cognitive vulnerability.
- Ventral intermediate nucleus of thalamus (VIM-DBS) — used primarily for tremor-predominant PD; less useful for the broader motor symptom complex.
The choice of target is made jointly by the movement disorder neurologist and the DBS-experienced neurosurgeon based on the dominant symptoms, age, cognitive profile, and risk tolerance.
What DBS does and does not do
The benefits, when DBS works well, are substantial:
- Reduction in off-time — typically 4-6 fewer off-hours per day in well-selected candidates.
- Reduction in dyskinesia — often dramatic, partly through direct effect and partly through reduced levodopa exposure.
- Reduction in tremor — particularly responsive to STN and VIM stimulation.
- Improvement in quality of life — consistently demonstrated in randomised trials at 6 months and 2 years, with effects shown to persist for 5-10+ years in some cohorts (Krack et al., 2019).
The limitations are equally important to understand:
- DBS does not slow disease progression. Cognitive decline, postural instability, freezing of gait that doesn't respond to levodopa, autonomic symptoms, sleep disorders, and non-motor symptoms generally continue to evolve.
- DBS does not help symptoms that don't respond to levodopa. This is the most important predictive rule: if a symptom does not improve with the person's best levodopa dose, it will not improve with DBS. This is why the levodopa challenge test is central to candidacy assessment.
- DBS does not cure Parkinson's. It modulates a circuit; the underlying neurodegeneration continues.
- DBS may worsen some non-motor symptoms. Speech, mood, cognition, and gait can all be affected. STN-DBS in particular has a documented association with apathy, depression, and impulse control changes in a minority of patients.
Who is a good candidate
The MDS DBS Patient Selection guidelines and the AAN practice parameters converge on a fairly consistent profile (Lang et al., 2006; Bronstein et al., 2011):
- PD diagnosis confirmed — typically by a movement disorder specialist, ideally with at least 4-5 years of disease duration to rule out atypical parkinsonism (PSP, MSA, CBD), which does not respond to DBS.
- Good levodopa response — the cardinal predictor. Formally tested with a levodopa challenge: motor scores in the off-medication state compared with peak on-medication state. A 30% or greater improvement is the threshold most centres use.
- Motor fluctuations or dyskinesia inadequately controlled by medication — this is the clinical reason for surgery. DBS is not for people whose medication is working well.
- No significant cognitive impairment — mild cognitive impairment is borderline; dementia is generally a contraindication. Neuropsychological testing is part of standard workup.
- No untreated depression, anxiety, or psychosis — these are not absolute contraindications but require stabilisation before surgery, because DBS can amplify mood symptoms.
- Age — historically under 70, but increasingly individualised. Older candidates can do well; biological age matters more than chronological age.
- Realistic expectations — the candidate and family understand what DBS will and will not do.
Who is generally not a good candidate
- People whose dominant problem is balance, falls, or freezing of gait that does not respond to levodopa. These symptoms generally do not improve with DBS and may worsen.
- People with PD dementia or significant cognitive impairment.
- People with active, untreated psychiatric illness.
- People with atypical parkinsonism (PSP, MSA, CBD) — these conditions do not respond to DBS.
- People whose motor symptoms are well controlled on medication without significant fluctuations or dyskinesia (DBS does not improve symptoms beyond the person's best on-medication state).
When in the disease course
The traditional teaching was to consider DBS late, after years of progressive motor complications. The EARLYSTIM trial (Schuepbach et al., 2013) changed this somewhat: it showed that DBS performed earlier — at the onset of motor complications, with median 7.5 years of disease duration — produced significantly better quality of life outcomes than continued best medical therapy. The implication is that DBS should be discussed at the first signs of disabling motor fluctuations, not deferred until the medication options are exhausted.
This does not mean DBS should be rushed. It means the conversation should start earlier, the assessment can be done earlier, and the surgery should be timed to when motor complications begin to interfere with quality of life — not after years of suffering through them.
What the assessment process looks like
A typical DBS evaluation at an experienced centre involves:
- Movement disorder neurology assessment — confirming PD diagnosis, levodopa challenge test, symptom inventory.
- Neurosurgical consultation — surgical risk assessment, target discussion.
- Neuropsychological evaluation — formal testing of memory, executive function, attention, language. Identifies cognitive vulnerabilities.
- Psychiatric evaluation — screens for depression, anxiety, impulse control disorders, psychosis.
- MRI brain — anatomy, ventricles, any structural lesions.
- Multidisciplinary team meeting — neurology, neurosurgery, neuropsychology, psychiatry review together.
- Family discussion — expectations, recovery, programming process, long-term commitment.
The assessment alone is a substantial process. Families should expect 2-4 months from referral to decision in most centres.
What surgery and recovery involve
The surgery is typically done in two stages:
- Stage 1 — electrode implantation. Often done with the person awake (light sedation) so the surgical team can test stimulation in real time. Several hours in the operating room. Some centres now do this asleep with intraoperative MRI guidance.
- Stage 2 — pulse generator implantation. Usually 1-2 weeks later, under general anaesthesia. Shorter procedure.
Recovery from surgery itself is typically 2-4 weeks. The more significant timeline is the programming — adjusting the stimulation parameters to optimise benefit and minimise side effects. This takes months. Most people make multiple visits in the first 6-12 months, gradually settling into a stable program.
What caregivers should ask the surgical team
- What is the expected reduction in off-time?
- What is the expected change in levodopa dose?
- What is the surgical complication rate at this centre, specifically?
- What are the cognitive and mood risks given this candidate's specific profile?
- What is the programming process and how often will we need to come back?
- Who manages the device long-term — the neurologist, the surgeon, a specialised nurse?
- What happens if the device malfunctions or the battery needs replacement (every 3-5 years for non-rechargeable; longer for rechargeable)?
- What is the centre's experience with people of similar age and disease stage?
Related questions
References
- Deuschl, G., Schade-Brittinger, C., Krack, P., et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine, 355(9), 896-908.
- Schuepbach, W. M., Rau, J., Knudsen, K., et al. (2013). Neurostimulation for Parkinson's disease with early motor complications (EARLYSTIM). New England Journal of Medicine, 368(7), 610-622.
- Krack, P., Volkmann, J., Tinkhauser, G., & Deuschl, G. (2019). Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Movement Disorders, 34(12), 1795-1810.
- Lang, A. E., Houeto, J. L., Krack, P., et al. (2006). Deep brain stimulation: preoperative issues. Movement Disorders, 21(S14), S171-S196.
- Bronstein, J. M., Tagliati, M., Alterman, R. L., et al. (2011). Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of Neurology, 68(2), 165.
- Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303.
- Goetz, C. G., et al. (2008). MDS-UPDRS. Movement Disorders, 23(15), 2129-2170.
Additional reading: the Michael J. Fox Foundation DBS resources; the Parkinson's Foundation surgical treatment materials; the International Parkinson and Movement Disorder Society clinical practice guidelines; the American Academy of Neurology PD practice parameters.
---
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full Parkinson's caregiver research overview for the complete framework.